Global Heparin Market is projected to expand at a CAGR of ~5% by 2026

Global Heparin Market Growth Forecast Analysis By Manufacturers - Reddy's Laboratories Ltd., Fresenius SE & Co KGaA, Baxter International Inc.
BRUSSELS - Jan. 3, 2023 - PRLog -- Heparin is an injectable anticoagulant prescription medicine used to treat and prevent the symptoms of blood clots caused by medical conditions or medical procedures. Additionally, it is utilized to make an anti-clotting surface inside a variety of medical devices, including test tubes and renal dialysis machines.

The Global Heparin Market is expected to grow at a rate of ~5% by 2026. The rising prevalence of chronic diseases such as venous thromboembolism, pulmonary embolism, renal diseases, and cardiovascular disorders, increasing geriatric population, high demand for anticoagulants, growing application of heparin in various surgeries such as orthopedic and heart surgeries, and the expanding availability of synthetic and semi-synthetic heparin mimetics that help in the treatment of cancer, coagulation, and inflammatory diseases are a few of the main factors driving the global heparin market.

Increasing Usage of Heparin in Various Applications Drives the Heparin Market
Anticoagulants work by decreasing the clotting ability of the blood. It helps to prevent the formation of clots as well as stop the further expansion of any existing clots. As a result, it may be used in a variety of applications, including:
  • Prevent or treat certain blood vessel, heart, and lung conditions
  • Prevent blood clotting during open-heart surgery, bypass surgery, kidney dialysis, and blood transfusions
  • Prevention of deep vein thrombosis
  • Prevention of a blood clot following percutaneous coronary intervention

Growing Adoption of Low Molecular Weight Unfractionated Heparin Over Heparin to Prevent Deep Vein Thrombosis or Pulmonary Embolism Fuels the Demand

Low-molecular-weight heparins have several advantages over UFH that have led to their increasing use for several thromboembolic indications such as deep vein thrombosis (DVT) and pulmonary embolism (PE) as well as atrial fibrillation (AF). In comparison to heparin, LMWH provides better bioavailability and a longer half-life, streamlined dose, predictable anticoagulant response, a reduced risk of heparin-induced thrombocytopenia (HIT), and a reduced risk of osteoporosis.

Explore Premium Report on Heparin Market @

The Potential Role of Heparin in Covid-19 Patients Boosts the Heparin Market Growth

Many patients with COVID-19 develop a clinically significant coagulopathy. COVID-19 infections can lead to an increased risk of blood clots. These blood clots can lead to individuals being admitted to hospital, or, unfortunately in severe cases, death. Similarly, patients with COVID-19 are at high risk for developing clinically significant large-vessel thrombosis. Thus, early usage of anticoagulation may reduce the risk of coagulopathy, microthrombus formation, and organ damage.

Media Contact
Medi-Tech Insights
+ 32 498 86 80 79
Email:*** Email Verified
Tags:Heparin Market
Location:Brussels - Brussels - Belgium
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Meditech insights PRs
Trending News
Most Viewed
Top Daily News

Like PRLog?
Click to Share